María José Goikoetxea

María José Goikoetxea

Auto-generated profile, based on publicly available information

María José Goikoetxea

Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2011 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
PCP. Cabrera‐Freitag
P. Cabrera‐Freitag
MGM. J. Goikoetxea
M. J. Goikoetxea
CBC. Beorlegui
C. Beorlegui
PGP. Gamboa
P. Gamboa
GGG. Gastaminza
G. Gastaminza
MSM. L. Sanz
M. L. Sanz

1 April 2016 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Open access
BGBe García
Be García
RMR Martínez-Aranguren
R Martínez-Aranguren
AAA Bernad Alonso
A Bernad Alonso
PGP Gamboa
P Gamboa
FBF Feo Brito
F Feo Brito
MSMl Sanz
Ml Sanz
JIACI - Journal of Investigational Allergology and Clinical Immunology

1 January 2010 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
MGM.J. Goikoetxea
M.J. Goikoetxea
PCP. Cabrera-Freitag
P. Cabrera-Freitag
MSM.L. Sanz
M.L. Sanz
MFM. Fernández-Benítez
M. Fernández-Benítez
In recent years, thanks to advances in molecular biology, allergological diagnosis has improved and specific IgE (sIgE) against an allergenic source has been transformed into sIgE against an allergenic protein or glycoprotein. This change, which has resulted in a more precise diagnosis of sensitisation, could explain the different dangers of certain molecular sensitisations and in many cases cross-reactivity phenomena, and could change indications for immunotherapy or clinical management. Here, we present two cases of children where the indication for immunotherapy and management of the disorder changed due to component-resolved diagnosis. However, the clinical history and skin prick tests should complement molecular in vitro diagnosis to improve routine clinical practice.

3 November 2016 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
CDC. D'Amelio
C. D'Amelio
GGG. Gastaminza
G. Gastaminza
OVO. Vega
O. Vega
ABA. Bernad
A. Bernad
RMR. C. Madamba
R. C. Madamba
MGM. J. Goikoetxea
M. J. Goikoetxea

11 July 2023 in Current Treatment Options in Allergy
Verified
Journal Article
Open access
PDF file
MBMarina Sabaté Brescó
Marina Sabaté Brescó
PQPaola Quan
Paola Quan
MGMaría José Goikoetxea
María José Goikoetxea
Purpose of review: To outline currently validated in vitro tests for the diagnosis of drug hypersensivity reactions (DHRs) and to provide useful strategies to optimise the utility of these tools. Recent findings: Regarding in vitro tests for DHR, the main concern, at present, is low sensitivity. Thus, most of the efforts are currently directed towards improving the existing techniques and developing new assays with better diagnostic performance. Summary: The management of DHRs is particularly challenging. Current strategies for diagnosis are focused on taking a thorough clinical history, evaluating sensitization using skin testing and performing supervised challenges. In vitro tests may potentially add information to the diagnostic algorithms for the management of DHRs. The presently available assays, however, pose significant limitations in terms of availability and validation. Maximizing their yield and accuracy, therefore, requires a tailored approach, focused on an appropriate clinical characterisation of the reaction. The time elapsed between drug administration and symptom presentation, as well as symptom duration, should be closely taken into consideration. In this review, existing validated in vitro techniques that may support the diagnosis of both immediate and non-immediate DHRs are summarised. Clues for optimizing their diagnostic yield are given.

22 July 2022 in Frontiers in Allergy
Verified
Journal Article
Open access
LSL. Sánchez-Ruano
L. Sánchez-Ruano
CFC. Fernández-Lozano
C. Fernández-Lozano
MFM. Ferrer
M. Ferrer
FGF. Gómez
F. Gómez
BHB. de la Hoz
B. de la Hoz
MGM. J. Goikoetxea
M. J. Goikoetxea
Background: Peanut-allergic patients from the Mediterranean region are predominantly sensitized to the lipid transfer protein (LTP) Ara h 9, and the peach LTP Pru p 3 seems to be the primary sensitizer. However, LTP sensitization in peanut allergy is not a predictive marker for clinically relevant symptoms.Objective: We aimed to identify sequential epitopes of IgE and IgG4 from Pru p 3 and Ara h 9 in peach-allergic patients sensitized to peanuts. We also sought to determine the differences in IgE and IgG4 binding between patients who had developed peanut allergy and those tolerating peanuts.Methods: A total of 46 peach-allergic patients sensitized to peanuts were selected. A total of 35 patients were allergic to peanuts (peanut-allergic group) and 11 were tolerant to peanuts (peanut-tolerant group). We measured sIgE and sIgG4 in peanut, peach, and their recombinant allergen (Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9) with fluorescence enzyme immunoassay. We examined the IgE and IgG4 binding to sequential epitopes using a peptide microarray corresponding to linear sequences of the LTPs Ara h 9 and Pru p 3 with a library of overlapping peptides with a length of 20 amino acids (aa) and an offset of 3 aa.Results: The frequency and the intensity of IgE recognition of Ara h 9 and Pru p 3 peptides were higher in the peanut-tolerant group than in the peanut-allergic group. We found four Ara h 9 peptides (p4, p14, p21, and p25) and four Pru p 3 peptides (p1, p3, p21, and p24) with a significantly elevated IgE recognition in peanut-tolerant patients. Only one peptide of Ara h 9 (p4) recognized by IgG4 was significantly elevated in the peanut-tolerant group. The IgG4/IgE ratio of Ara h 9 peptide 4 was significantly higher in peanut-tolerant patients than in peanut-allergic patients, while no significant differences were observed in the IgG4/IgE ratio of this peptide in Pru p 3.Conclusion: Although we found significant differences in IgE and IgG4 recognition of Ara h 9 and Pru p 3 between peanut-tolerant and peanut-allergic patients (all of whom were allergic to peach), polyclonal IgE peptide recognition of both LTPs was observed in peach-allergic patients tolerating peanuts. However, the IgG4 blocking antibodies against Ara h 9 peptide 4 could provide an explanation for the absence of clinical reactivity in peanut-tolerant peach-allergic patients. Further studies are needed to validate the usefulness of IgG4 antibodies against Ara h 9 peptide 4 for peanut allergy diagnosis.